Familial hypocalciuric hypercalcemia: genes and variants
Familial hypocalciuric hypercalcemia is linked to 2 analyzed proteins (CASR and GNA11). 85 DNA variants are known to cause it; 1,188 more are uncertain, and 18 of those already look disease-causing on computable evidence.
Last updated 2026-09-30. Research information, not medical advice.
Also known as: familial hypocalciuric hypercalcemia 1; familial hypocalciuric hypercalcemia 2; Familial hypocalciuric hypercalcemia type 1; Familial hypocalciuric hypercalcemia type 2
Genes linked to Familial hypocalciuric hypercalcemia
CASR: Extracellular calcium-sensing receptor
It senses extracellular calcium in the parathyroid gland and kidney and adjusts parathyroid-hormone secretion and renal calcium handling accordingly. Loss-of-function variants cause familial hypocalciuric hypercalcemia or neonatal severe hyperparathyroidism, whereas activating variants cause autosomal dominant hypocalcemia.
81 disease-causing and 1,174 uncertain variants in CASR are linked to Familial hypocalciuric hypercalcemia.
GNA11: Guanine nucleotide-binding protein subunit alpha-11
It transmits signals from Gq-coupled receptors to phospholipase C and downstream calcium and protein-kinase-C pathways. Germline activating variants can cause autosomal dominant hypocalcemia, while somatic activating variants drive uveal melanoma and some vascular lesions.
4 disease-causing and 14 uncertain variants in GNA11 are linked to Familial hypocalciuric hypercalcemia.
Where Familial hypocalciuric hypercalcemia variants cluster
- CASR Ligand-binding 1 (LB1) (positions 22–188): 24 of 81 disease-causing changes, 1.9× more than its size predicts.
- CASR Cysteine-rich (CR) (positions 542–612): 13 of 81 disease-causing changes, 2.4× more than its size predicts.
- CASR Transmembrane (positions 806–828): 4 of 81 disease-causing changes, 2.3× more than its size predicts.
- CASR Intracellular loop 3 (ICL3) (positions 790–805): 3 of 81 disease-causing changes, 2.5× more than its size predicts.
- CASR Interaction with RNF19A (positions 880–900): 3 of 81 disease-causing changes, 1.9× more than its size predicts.
Known disease-causing variants in Familial hypocalciuric hypercalcemia
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| CASR E127K | 127 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR C582S | 582 | Cysteine-rich (CR) | Disease-causing (★★) |
| CASR C582Y | 582 | Cysteine-rich (CR) | Disease-causing (★★) |
| CASR M1T | 1 | Disease-causing (★★) | |
| CASR M1V | 1 | Disease-causing (★★) | |
| CASR R66C | 66 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR R66H | 66 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR E127G | 127 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR E127A | 127 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR R220Q | 220 | Ligand-binding 2 (LB2) | Disease-causing (★★) |
| CASR N64D | 64 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR L125P | 125 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR F128L | 128 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR R172G | 172 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR R185Q | 185 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR P221L | 221 | Ligand-binding 2 (LB2) | Disease-causing (★★) |
| CASR R227Q | 227 | Ligand-binding 2 (LB2) | Disease-causing (★★) |
| CASR R227L | 227 | Ligand-binding 2 (LB2) | Disease-causing (★★) |
| CASR G553R | 553 | Cysteine-rich (CR) | Disease-causing (★★) |
| CASR R69H | 69 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR G143E | 143 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR D217Y | 217 | Ligand-binding 2 (LB2) | Disease-causing (★★) |
| CASR Y218C | 218 | Ligand-binding 2 (LB2) | Disease-causing (★★) |
| CASR I555T | 555 | Cysteine-rich (CR) | Disease-causing (★★) |
| CASR R680H | 680 | Transmembrane | Disease-causing (★★) |
| CASR R680C | 680 | Transmembrane | Disease-causing (★★) |
| CASR R886P | 886 | Interaction with RNF19A | Disease-causing (★★) |
| CASR R886W | 886 | Interaction with RNF19A | Disease-causing (★★) |
| GNA11 R60C | 60 | G-alpha | Disease-causing (★★) |
| CASR S53P | 53 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR G143R | 143 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR E604K | 604 | Cysteine-rich (CR) | Disease-causing (★★) |
| CASR P55L | 55 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR T151M | 151 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR D190G | 190 | Ligand-binding 2 (LB2) | Disease-causing (★★) |
| CASR C395R | 395 | Extracellular | Disease-causing (★★) |
| CASR Q459R | 459 | Extracellular | Disease-causing (★★) |
| CASR R465Q | 465 | Extracellular | Disease-causing (★★) |
| CASR G509R | 509 | Extracellular | Disease-causing (★★) |
| CASR G613E | 613 | Transmembrane | Disease-causing (★★) |
| CASR G670R | 670 | Extracellular | Disease-causing (★★) |
| CASR V689M | 689 | Transmembrane | Disease-causing (★★) |
| CASR V728F | 728 | Transmembrane | Disease-causing (★★) |
| CASR P748Q | 748 | Extracellular | Disease-causing (★★) |
| CASR E767K | 767 | Extracellular | Disease-causing (★★) |
| CASR F788C | 788 | Transmembrane | Disease-causing (★★) |
| CASR R795W | 795 | Intracellular loop 3 (ICL3) | Disease-causing (★★) |
| CASR P798L | 798 | Intracellular loop 3 (ICL3) | Disease-causing (★★) |
| CASR M811V | 811 | Transmembrane | Disease-causing (★★) |
| CASR V817I | 817 | Transmembrane | Disease-causing (★★) |
| CASR F832S | 832 | Extracellular | Disease-causing (★★) |
| CASR N178D | 178 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR N802S | 802 | Intracellular loop 3 (ICL3) | Disease-causing (★★) |
| CASR M1R | 1 | Disease-causing (★) | |
| CASR R220P | 220 | Ligand-binding 2 (LB2) | Disease-causing (★) |
| GNA11 T54M | 54 | G-alpha | Disease-causing (★) |
| CASR A168V | 168 | Ligand-binding 1 (LB1) | Disease-causing (★) |
| CASR D215H | 215 | Ligand-binding 2 (LB2) | Disease-causing (★) |
| CASR R551K | 551 | Cysteine-rich (CR) | Disease-causing (★) |
| CASR G557E | 557 | Cysteine-rich (CR) | Disease-causing (★) |
Showing 60 of 85.
Uncertain variants in Familial hypocalciuric hypercalcemia that look disease-causing
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| CASR R185L | 185 | Ligand-binding 1 (LB1) | Conflicting reports (★) | +6: in a 3D region that tolerates change poorly (1A); R185Q at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.99 |
| CASR Y218H | 218 | Ligand-binding 2 (LB2) | Conflicting reports (★) | +6: 6 other pathogenic changes within 3 positions; Y218C at the same position is pathogenic; seen in 6.8e-07 of gnomAD DNA copies; AlphaMissense 1.00 |
| CASR C582R | 582 | Cysteine-rich (CR) | Uncertain (★) | +6: 3 other pathogenic changes within 3 positions; C582S at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| CASR C562Y | 562 | Cysteine-rich (CR) | Uncertain (★★) | +6: 2 other pathogenic changes within 3 positions; C562F at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| CASR G549E | 549 | Cysteine-rich (CR) | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; G549R at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| CASR D215N | 215 | Ligand-binding 2 (LB2) | Uncertain (★) | +6: 3 other pathogenic changes within 3 positions; D215H at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.95 |
| CASR Y218N | 218 | Ligand-binding 2 (LB2) | Uncertain (★) | +6: 6 other pathogenic changes within 3 positions; Y218C at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| CASR R62K | 62 | Ligand-binding 1 (LB1) | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; R62M at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.85 |
| CASR R69C | 69 | Ligand-binding 1 (LB1) | Uncertain (★★) | +6: 3 other pathogenic changes within 3 positions; R69H at the same position is pathogenic; seen in 6.8e-07 of gnomAD DNA copies; AlphaMissense 0.92 |
| CASR P55S | 55 | Ligand-binding 1 (LB1) | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; P55L at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.95 |
| CASR D217G | 217 | Ligand-binding 2 (LB2) | Uncertain (★★) | +6: 5 other pathogenic changes within 3 positions; D217Y at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.76 |
| CASR A168D | 168 | Ligand-binding 1 (LB1) | Uncertain (★) | +6: in a 3D region that tolerates change poorly (1A); A168V at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.91 |
| CASR G557R | 557 | Cysteine-rich (CR) | Uncertain (★) | +6: 3 other pathogenic changes within 3 positions; G557E at the same position is pathogenic; seen in 6.8e-07 of gnomAD DNA copies; AlphaMissense 0.79 |
| CASR G553V | 553 | Cysteine-rich (CR) | Uncertain (★★) | +6: 3 other pathogenic changes within 3 positions; G553R at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.94 |
| CASR G557W | 557 | Cysteine-rich (CR) | Uncertain (★) | +6: 3 other pathogenic changes within 3 positions; G557E at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.79 |
| CASR F128I | 128 | Ligand-binding 1 (LB1) | Uncertain (★) | +6: 5 other pathogenic changes within 3 positions; F128L at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.74 |
| CASR P221Q | 221 | Ligand-binding 2 (LB2) | Uncertain (★) | +6: 4 other pathogenic changes within 3 positions; P221L at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.82 |
| CASR R172S | 172 | Ligand-binding 1 (LB1) | Uncertain | +6: 2 other pathogenic changes within 3 positions; R172G at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.77 |
Which prediction tools work for Familial hypocalciuric hypercalcemia
How often each tool ranks a disease-causing variant above a harmless one (AUROC × 100).
- CADD: 98 out of 100
- PolyPhen-2: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CATVariant: 94 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- phyloP: 93 out of 100
- SIFT: 85 out of 100
Same protein, different disease
- Autosomal dominant hypocalcemia is also caused by CASR variants; they fall in the same places as the Familial hypocalciuric hypercalcemia variants (69 disease-causing).
- Nephrolithiasis/nephrocalcinosis is also caused by CASR variants; they fall in the same places as the Familial hypocalciuric hypercalcemia variants (14 disease-causing).
- Neonatal severe primary hyperparathyroidism is also caused by CASR variants; they fall in the same places as the Familial hypocalciuric hypercalcemia variants (11 disease-causing).
- Familial hyperparathyroidism or Hypocalciuric hypercalcaemia is also caused by CASR variants; they fall partly in the same places as the Familial hypocalciuric hypercalcemia variants (5 disease-causing).
- Autosomal dominant hypocalcemia is also caused by GNA11 variants; they fall mostly in different places as the Familial hypocalciuric hypercalcemia variants (6 disease-causing).
Diseases related to Familial hypocalciuric hypercalcemia
- Autosomal dominant hypocalcemia, also linked to CASR and GNA11
- Familial hypoparathyroidism, also linked to CASR and GNA11
- Hypertrophic cardiomyopathy, also linked to CASR
- Epilepsy, idiopathic generalized, susceptibility to, 13, also linked to CASR
- Idiopathic generalized epilepsy, also linked to CASR
- Nephrolithiasis/nephrocalcinosis, also linked to CASR
- Vascular malformation, also linked to GNA11
- Neonatal severe primary hyperparathyroidism, also linked to CASR
- Familial hyperparathyroidism or Hypocalciuric hypercalcaemia, also linked to CASR
- Familial multiple nevi flammei, also linked to GNA11
- Chronic kidney disease, also linked to CASR
Frequently asked questions
Which genes are linked to Familial hypocalciuric hypercalcemia?
In CATVariant, Familial hypocalciuric hypercalcemia is linked to 2 analyzed proteins: CASR (Extracellular calcium-sensing receptor) and GNA11 (Guanine nucleotide-binding protein subunit alpha-11).
How many genetic variants are linked to Familial hypocalciuric hypercalcemia?
1,297 variants: 85 are classified as disease-causing (pathogenic or likely pathogenic) in ClinVar and 1,188 are of uncertain significance or have conflicting reports.
Which uncertain variants in Familial hypocalciuric hypercalcemia look disease-causing?
18 uncertain variants reach the likely-pathogenic range of the ACMG/AMP points scale on computable evidence, for example CASR R185L, CASR Y218H, CASR C582R, CASR C562Y and CASR G549E. These are leads for expert review, not diagnoses.
Which variant effect predictor works best for Familial hypocalciuric hypercalcemia?
Among tools not trained on clinical labels, CADD separates this disease's known disease-causing variants from harmless ones best (AUROC 0.98, based on 37 disease-causing and 11 harmless variants).
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from the latest public CATVariant analysis of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center